Ino

Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, May 11, 2022
COVID-19, Pulmonary hypertension, U.S. Securities and Exchange Commission, Tesa SA, University, Sarcoidosis, Nasdaq, Ino, GLOBE, Company, Private Securities Litigation Reform Act, Public expenditure, Food, Research, MVPA, ST, Patient, Degenerative disease, Security (finance), Survival, Clinical trial, Paul Fildes, Diagnosis, Annual report, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hepatic artery proper, PVR, Bellerophon, Trial of the century, Therapy, Pharmaceutical industry, Cryptocurrency

WARREN, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2022.

Key Points: 
  • WARREN, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2022.
  • The Phase 3 program builds on positive top-line results from the Companys previously reported Phase 2 studies for INOpulse for the treatment of fILD.
  • Research and development expenses for the first quarter ended March 31, 2022 were $4.4 million, compared to $3.6 million in the first quarter of 2021.
  • General and administrative expenses for the first quarter ended March 31, 2022 were $1.2 million, compared to $2.3 million in the first quarter of 2021.

Claritas Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107

Retrieved on: 
Tuesday, April 5, 2022
CPAP, USD, Human, Therapy, Trial of the century, Standards for Reporting Enzymology Data, Hypertensive emergency, Pharmacokinetics, Adult, Pulmonary hypertension, Journal of Empirical Research on Human Research Ethics, CLAS, Wound healing, Biomedical Advanced Research and Development Authority, Times New Roman, Medicine, CEO, Human services, Report, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, TSX, Office of Inspector General, U.S. Department of Health and Human Services, Injury, Mouth, Nitric oxide, Nobel Prize, Safety, Ino, Time, CA, GLOBE, Paganini Competition, Disorder, Degenerative disease, Solution, COVID, SAN, Development, OTC, Patient, Disease, Pharmaceutical industry, Fertilizer, PPHN

HREC approval is the final regulatory step prior to initiation of the clinical study.

Key Points: 
  • HREC approval is the final regulatory step prior to initiation of the clinical study.
  • In addition to the Phase 2a clinical study in PAH, Claritas will also initiate a Phase 2 study in PPHN.
  • Following completion of the Phase 1 study, Claritas will again seek such funding for the costs of Phase 2 studies of R-107 in the treatment of
    sepsis and ARDS.
  • Claritas Pharmaceuticals, Inc. ("Claritas") is committed to developing new treatments for a variety of diseases and disorders, by discovering, developing, manufacturing, and delivering innovative human therapeutics.

Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results

Retrieved on: 
Thursday, March 31, 2022
Company, Therapy, Degenerative disease, Hepatic artery proper, Private Securities Litigation Reform Act, Diagnosis, Tesa SA, Clinical trial, Pulmonary hypertension, Public expenditure, Survival, Bellerophon, Research, Conference, U.S. Securities and Exchange Commission, Security (finance), ST, Trial of the century, Ino, PVR, Nasdaq, COVID-19, GLOBE, Income, Sarcoidosis, MVPA, Paul Fildes, Annual report, University, Patient, Pharmaceutical industry, Animal

WARREN, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the year ended December 31, 2021.

Key Points: 
  • WARREN, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the year ended December 31, 2021.
  • Our balance sheet, with $24.7 million in cash and cash equivalents, provides us with continued resources to advance our late-stage development programs.
  • The Phase 3 program builds on positive top-line results from the Companys previously reported Phase 2 studies for INOpulse for the treatment of fILD.
  • The decrease was primarily attributable to the decrease in expenses related to the discontinuation of the COVID-19 trial in 2021.

The Global Inhaled Nitric Oxide Delivery Systems Market is Estimated to Grow from USD 247.5 Million in 2020 to USD 434.2 Million by 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 17, 2022
Medical Devices, Health, Diamond, Asthma, Nitric oxide, AHRF, INO, Hypoxic pulmonary vasoconstriction, Incidence, Pulmonary hypertension, HRF, World, Sepsis, Safety, Ino, WHO, Application, Social support, Degenerative disease, USD, Pneumonia, Public health, Disease, World Health Organization, COVID-19, Toxicity, CAGR, Pharmaceutical industry

The "Inhaled Nitric Oxide Delivery Systems Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Inhaled Nitric Oxide Delivery Systems Market" report has been added to ResearchAndMarkets.com's offering.
  • The global Inhaled Nitric Oxide Delivery Systems market is estimated to grow from USD 247.5 million in 2020 to USD 434.2 million by 2027, at a CAGR of 6.9%.
  • Inhaled Nitric Oxide (INO), a minimally invasive therapy, is being investigated for the treatment of diseases linked with reversible pulmonary vasoconstriction and pulmonary hypertension in children and adults.
  • The key players profiled in Inhaled Nitric Oxide Delivery Systems market analysis are:

Third Pole Therapeutics Closes $25M Financing - eNOfit™ Wearable Device Now Ready for Clinical Trials

Retrieved on: 
Thursday, February 3, 2022
NO, Inhalation, Risk, Patient, Atmosphere, Therapy, Physician, Pulmonary hypertension, Technology, Adoption, Inflammation, Infection, Adult, Cystic fibrosis, Interstitial lung disease, Ino, COPD, Company, Heart failure, Electricity, Travel, Nitric oxide, Chronic obstructive pulmonary disease, FDA, Pulmonary fibrosis, ILD, Hospital, Pharmaceutical industry, Third Pole, Third Pole

WALTHAM, Mass., Feb. 3, 2022 /PRNewswire/ -- Third Pole Therapeutics , a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today that it has achieved several significant milestones that include closing a $25M round of financing, and that eNOfit, the Company's fully miniaturized wearable device, is ready for clinical trials.

Key Points: 
  • WALTHAM, Mass., Feb. 3, 2022 /PRNewswire/ -- Third Pole Therapeutics , a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today that it has achieved several significant milestones that include closing a $25M round of financing, and that eNOfit, the Company's fully miniaturized wearable device, is ready for clinical trials.
  • We also welcome our new investors who have joined us in support of this important mission."
  • Two decades later, Third Pole has successfully created a scalable technology that delivers nitric oxide for inhalation, instantly, on-demand, and in unlimited quantities.
  • Third Pole's two novel platforms include eNOfit a miniaturized wearable device for home and travel and eNOcare, a lightweight portable in-hospital device.

Third Pole Therapeutics to Participate in H.C. Wainwright BioConnect and BIO Partnering at JPM during J.P. Morgan 40th Annual Healthcare Conference

Retrieved on: 
Thursday, January 6, 2022
Therapy, Interstitial lung disease, BIO, Infection, Electricity, Company, Patient, SynCo Bio Partners, Conference, Atmosphere, Hospital, Cystic fibrosis, ILD, Ino, Travel, Chronic obstructive pulmonary disease, COPD, Nitric oxide, Industry, JPM, Pulmonary fibrosis, Pharmaceutical industry, Third Pole

CEO Bill Athenson will present recent business and clinical development activities and anticipated milestones during the H.C. Wainwright BioConnect Conference.

Key Points: 
  • CEO Bill Athenson will present recent business and clinical development activities and anticipated milestones during the H.C. Wainwright BioConnect Conference.
  • Mr. Athenson will also be available for virtual one-on-one meetings with registered investors and pharmaceutical companies at BIO Partnering at JPM.
  • Third Pole Therapeutics develops and delivers critical life-sustaining cardio-pulmonary therapies.
  • Third Pole's two novel platforms include a miniaturized wearable device for home and travel and a lightweight portable in-hospital device.

Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries

Retrieved on: 
Tuesday, January 4, 2022
COVID-19, Scientific Reports, Disorder, Burn, Injury, Mortality, PAH, Human services, Sepsis, Ino, ECMO, Sexual dysfunction, CEO, OTC, USD, Acute respiratory distress syndrome, Dressing (medical), Burns, Pulmonary hypertension, Royal Brompton Hospital, Wound healing, Respiratory distress syndrome, Dysmenorrhea, Trial of the century, Report, PPHN, RDS, CLAS, Death, CA, Human, Nitric oxide, SAN, GLOBE, Female, Anal fissure, Office of Inspector General, U.S. Department of Health and Human Services, Science, COVID, Degenerative disease, Disease, Â, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Solution, Therapy, Patient, Standards for Reporting Enzymology Data, TSX, Mouth, Pharmaceutical industry, Times New Roman

Claritas is poised to accelerate development of R-107 for treatment of numerous diseases, disorders and injuries, stated Robert Farrell, Claritas President and CEO.

Key Points: 
  • Claritas is poised to accelerate development of R-107 for treatment of numerous diseases, disorders and injuries, stated Robert Farrell, Claritas President and CEO.
  • Our development strategy is straightforward, as follows:
    Phase 1 Study in Q1 2022: The first step is completion of our Phase 1 clinical study to demonstrate that R-107 is safe in humans.
  • Depending on how it is administered, R-107 can target multiple diseases, disorders, and injuries.
  • Claritas Pharmaceuticals, Inc. ("Claritas") is committed to developing new treatments for a variety of diseases and disorders, by discovering, developing, manufacturing, and delivering innovative human therapeutics.

Claritas to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns

Retrieved on: 
Wednesday, December 22, 2021
Mortality, Blood, TSX, Lung, Program, Pregnancy, Placenta, Chronic lung disease, Patient, Sale, Hypertensive emergency, ECMO, USD, Disease, Infection, Stroke, Nitric oxide, Skin, Agent handling, Travel, Ino, Bleeding, Solution, CA, Brain, CLAS, SAN, OTC, Pulmonary hypertension, GLOBE, Infant, Oxygen, PPHN, Pharmaceutical industry, Medical imaging, Times New Roman

Inhaled nitric oxide (iNO) is the only drug approved for the treatment of PPHN.

Key Points: 
  • Inhaled nitric oxide (iNO) is the only drug approved for the treatment of PPHN.
  • Claritas expects to initiate a Phase 2 study of R-107 in the treatment of PPHN by year-end 2022.
  • Claritas believes that R-107 could address this issue, due in part to its ease of administration, and projected lower cost vis--vis iNO administration.
  • Claritas Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs.

Bellerophon Reports Positive Top-Line Data from Phase 2 Acute Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Sarcoidosis

Retrieved on: 
Friday, December 17, 2021
Therapy, U.S. Securities and Exchange Commission, PVR, Company, Clinical trial, Private Securities Litigation Reform Act, Nasdaq, Public expenditure, Hepatic artery proper, Tesa SA, Annual report, Survival, Patient, Mortality, Pulmonary hypertension, Disease, Cincinnati, Sarcoidosis, Program, Ino, University, GLOBE, Principal investigator, Pharmaceutical industry, Medicine, Bellerophon

WARREN, N.J., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced positive top-line data from a recently completed Phase 2 dose escalation study (PULSE-PHPF-002) evaluating the acute hemodynamic benefit of INOpulse® via right heart catheterization for the treatment of pulmonary hypertension associated with sarcoidosis (PH-Sarc).

Key Points: 
  • The Phase 2 trial was designed as a proof of concept study to determine if iNO could demonstrate hemodynamic benefit in PH-Sarc.
  • Key results included:
    All 8 subjects demonstrated decreases in mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR) across the doses of INOpulse utilized in the study.
  • No treatment-emergent adverse events (TEAEs) or serious adverse events (TESAEs) occurred during the acute hemodynamic dose escalation phase of the study.
  • Sarcoidosis associated pulmonary hypertension has a median survival of approximately five years after development of the pulmonary hypertension.

INOVIO Presents Clinical Results of its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 2020 Annual Meeting

Retrieved on: 
Friday, November 20, 2020
Branches of biology, Biology, Medicine, Cancer treatments, Lactams, Prodrugs, Temozolomide, Teratogens, Inovio Pharmaceuticals, Plasmid, Ino

The study demonstrated that INO-5401 + INO-9012 with Libtayo, radiation (RT) and temozolomide (TMZ) are tolerable, immunogenic, and may improve median survival for patients with newly diagnosed GBM.

Key Points: 
  • The study demonstrated that INO-5401 + INO-9012 with Libtayo, radiation (RT) and temozolomide (TMZ) are tolerable, immunogenic, and may improve median survival for patients with newly diagnosed GBM.
  • INO-5401, INO-9012 and Libtayo, and the combination of these products have not been approved or evaluated by any Regulatory Authority worldwide for the treatment of newly diagnosed GBM.
  • INOVIO's DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using INOVIO's proprietary hand-held smart device called CELLECTRA.
  • INOVIO's DNA medicines do not interfere with or change in any way an individual's own DNA.